Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.55 |
| ▸ | CDK6 | Q00534 | 7/20 | 0.54 |
| ▸ | CDK4 | P11802 | 4/20 | 0.54 |
| ▸ | CSF1R | P07333 | 3/20 | 0.54 |
| ▸ | JAK2 | O60674 | 8/20 | 0.53 |
| ▸ | FLT3 | P36888 | 7/20 | 0.53 |
| ▸ | CDK1 | P06493 | 2/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.49 |
| ▸ | CCND3 | P30281 | 2/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | CCND1 | P24385 | 2/20 | 0.48 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29606969 | 1.00 | EGFR (0.55) | EGFRCDK6CDK4CSF1RJAK2 | |
| SCHEMBL24664385 | 0.90 | CDK6 (0.52) | EGFRCDK6CDK4CSF1RJAK2 | |
| SCHEMBL29608582 | 0.90 | CDK6 (0.52) | EGFRCDK6CDK4CSF1RJAK2 | |
| SCHEMBL24664303 | 0.88 | CSF1R (0.63) | EGFRCDK6CDK4CSF1RJAK2 | |
| SCHEMBL24664300 | 0.86 | CDK2 (0.59) | CDK6CDK4CSF1RJAK2FLT3 | |
| SCHEMBL29607128 | 0.84 | JAK2 (0.51) | EGFRCDK6CDK4CSF1RJAK2 | |
| SCHEMBL24663787 | 0.84 | JAK2 (0.51) | EGFRCDK6CDK4CSF1RJAK2 | |
| SCHEMBL29608982 | 0.83 | CDK6 (0.67) | CDK6CDK4CSF1RJAK2FLT3 | |
| SCHEMBL24664426 | 0.83 | CDK6 (0.67) | CDK6CDK4CSF1RJAK2FLT3 | |
| SCHEMBL24664372 | 0.80 | CSF1R (0.55) | CDK6CDK4CSF1RJAK2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220298140-A1 | 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2022-09-22 | — | — | US | disclosed |
| CN-114423750-A | 2, 4-disubstituted pyrimidine derivative and preparation method and application thereof | 成都赜灵生物医药科技有限公司 | 2022-04-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298140-A1 | 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | JAK2, FLT3, JAK1 | EGFR 555/4885CDK6 92/4885CDK4 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.